The BDNF


Journal

Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835

Informations de publication

Date de publication:
02 2021
Historique:
received: 19 10 2018
accepted: 14 02 2019
revised: 19 01 2019
pubmed: 23 3 2019
medline: 15 5 2021
entrez: 23 3 2019
Statut: ppublish

Résumé

In Alzheimer's disease (AD), a single-nucleotide polymorphism in the gene encoding brain-derived neurotrophic factor (BDNF

Identifiants

pubmed: 30899092
doi: 10.1038/s41380-019-0404-6
pii: 10.1038/s41380-019-0404-6
pmc: PMC6754794
mid: NIHMS1521850
doi:

Substances chimiques

Amyloid beta-Peptides 0
Brain-Derived Neurotrophic Factor 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

614-628

Subventions

Organisme : NIA NIH HHS
ID : U24 AG021886
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG058676
Pays : United States
Organisme : NIA NIH HHS
ID : K01 AG053474
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG026276
Pays : United States
Organisme : Medical Research Council
ID : MR/009076/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023784/1
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : P30 NS048056
Pays : United States
Organisme : NIA NIH HHS
ID : UF1 AG032438
Pays : United States
Organisme : NIA NIH HHS
ID : K23 AG049087
Pays : United States
Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG032438
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB009352
Pays : United States
Organisme : NINDS NIH HHS
ID : P30 NS098577
Pays : United States

Références

Bekinschtein P, Cammarota M, Katche C, Slipczuk L, Rossato JI, Goldin A, et al. BDNF is essential to promote persistence of long-term memory storage. Proc Natl Acad Sci USA. 2008;105:2711–6.
pubmed: 18263738 pmcid: 2268201
Song M, Martinowich K, Lee FS. BDNF at the synapse: why location matters. Mol Psychiatry. 2017;22:1370–5.
pubmed: 28937692 pmcid: 5646361
Hall J, Thomas KL, Everitt BJ. Rapid and selective induction of BDNF expression in the hippocampus during contextual learning. Nat Neurosci. 2000;3:533–5.
pubmed: 10816306
Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol. 2001;63:71–124.
pubmed: 11040419
Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol. 2014;220:223–50.
pubmed: 24668475
Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27:1372–84.
pubmed: 16289476
de Wilde MC, Overk CR, Sijben JW, Masliah E. Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement. 2016;12:633–44.
pubmed: 26776762 pmcid: 5058345
Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain. 2009;132(Pt 4):1067–77.
pubmed: 19251758 pmcid: 2668943
Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci. 2013;14:401–16.
pubmed: 23674053
Michalski B, Corrada MM, Kawas CH, Fahnestock M. Brain-derived neurotrophic factor and TrkB expression in the "oldest-old," the 90+ Study: correlation with cognitive status and levels of soluble amyloid-beta. Neurobiol Aging. 2015;36:3130–9.
pubmed: 26410307 pmcid: 4756909
Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009;15:331–7.
pubmed: 19198615 pmcid: 2838375
Jiao SS, Shen LL, Zhu C, Bu XL, Liu YH, Liu CH, et al. Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease. Transl Psychiatry. 2016;6:e907.
pubmed: 27701410 pmcid: 5315549
Nagahara AH, Mateling M, Kovacs I, Wang L, Eggert S, Rockenstein E, et al. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci. 2013;33:15596–602.
pubmed: 24068826 pmcid: 3782628
Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257–69.
pubmed: 12553913
Hao R, Qi Y, Hou DN, Ji YY, Zheng CY, Li CY, et al. BDNF val66met polymorphism impairs hippocampal long-term depression by down-regulation of 5-HT3 receptors. Front Cell Neurosci. 2017;11:306.
pubmed: 29075179 pmcid: 5643500
Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, Schaffner SF, et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry. 2010;15:810–5.
pubmed: 19255578
Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, et al. BDNF Val66Met, Abeta amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiol Aging. 2013;34:2457–64.
pubmed: 23769397
Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, et al. Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study. PLoS One. 2014;9:e86498.
pubmed: 24475133 pmcid: 3903533
Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PJ, Ames D, et al. APOE and BDNF polymorphisms moderate amyloid beta-related cognitive decline in preclinical Alzheimer's disease. Mol Psychiatry. 2015;20:1322–8.
pubmed: 25288138
Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, et al. BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain. 2016;139(Pt 10):2766–77.
pubmed: 27521573 pmcid: 5815565
Lim YY, Hassenstab J, Goate A, Fagan AM, Benzinger TLS, Cruchaga C, et al. Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. Ann Neurol. 2018;84:424–35.
pubmed: 30014553 pmcid: 6153076
Kambeitz JP, Bhattacharyya S, Kambeitz-Ilankovic LM, Valli I, Collier DA, McGuire P. Effect of BDNF val(66)met polymorphism on declarative memory and its neural substrate: a meta-analysis. Neurosci Biobehav Rev. 2012;36:2165–77.
pubmed: 22813992
Harrisberger F, Spalek K, Smieskova R, Schmidt A, Coynel D, Milnik A, et al. The association of the BDNF Val66Met polymorphism and the hippocampal volumes in healthy humans: a joint meta-analysis of published and new data. Neurosci Biobehav Rev. 2014;42:267–78.
pubmed: 24674929
Park KH, Noh Y, Choi EJ, Kim H, Chun S, Son YD. Functional connectivity of the hippocampus in early- and vs. late-onset alzheimer's disease. J Clin Neurol. 2017;13:387–93.
pubmed: 29057631 pmcid: 5653627
Allen G, Barnard H, McColl R, Hester AL, Fields JA, Weiner MF, et al. Reduced hippocampal functional connectivity in Alzheimer disease. Arch Neurol. 2007;64:1482–7.
pubmed: 17923631
Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA. 2004;101:4637–42.
pubmed: 15070770 pmcid: 384799
Tahmasian M, Pasquini L, Scherr M, Meng C, Forster S, Mulej Bratec S, et al. The lower hippocampus global connectivity, the higher its local metabolism in Alzheimer disease. Neurology. 2015;84:1956–63.
pubmed: 25878180
Sorg C, Riedl V, Muhlau M, Calhoun VD, Eichele T, Laer L, et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2007;104:18760–5.
pubmed: 18003904 pmcid: 2141850
Pasquini L, Scherr M, Tahmasian M, Meng C, Myers NE, Ortner M, et al. Link between hippocampus' raised local and eased global intrinsic connectivity in AD. Alzheimers Dement. 2015;11:475–84.
pubmed: 25043909
La Joie R, Landeau B, Perrotin A, Bejanin A, Egret S, Pelerin A, et al. Intrinsic connectivity identifies the hippocampus as a main crossroad between Alzheimer's and semantic dementia-targeted networks. Neuron. 2014;81:1417–28.
pubmed: 24656258
Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, et al. Dominantly inherited Alzheimer network: facilitating research and clinical trials. Alzheimers Res Ther. 2013;5:48.
pubmed: 24131566 pmcid: 3978584
Jones DT, Knopman DS, Gunter JL, Graff-Radford J, Vemuri P, Boeve BF, et al. Cascading network failure across the Alzheimer's disease spectrum. Brain. 2016;139(Pt 2):547–62.
pubmed: 26586695
Thomas JB, Brier MR, Bateman RJ, Snyder AZ, Benzinger TL, Xiong C, et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA Neurol. 2014;71:1111–22.
pubmed: 25069482 pmcid: 4240274
Rodriguez-Gomez O, Sanabria A, Perez-Cordon A, Sanchez-Ruiz D, Abdelnour C, Valero S, et al. FACEHBI: a prospective study of risk factors, biomarkers and cognition in a cohort of individuals with subjective cognitive decline. study rationale and research protocols. J Prev Alzheimers Dis. 2017;4:100–8.
pubmed: 29186280
Jessen F, Spottke A, Boecker H, Brosseron F, Buerger K, Catak C, et al. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). Alzheimer's Res Ther. 2018;10:15.
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795–804.
pubmed: 22784036 pmcid: 3474597
Franzmeier N, Duzel E, Jessen F, Buerger K, Levin J, Duering M, et al. Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. Brain. 2018;141:1186–1200.
pubmed: 29462334 pmcid: 5888938
Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8:369ra178.
pubmed: 27974666 pmcid: 5385711
Benzinger TL, Blazey T, Jack CR Jr., Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci USA. 2013;110:E4502–4509.
pubmed: 24194552 pmcid: 3839740
Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal fluid Abeta42/40 corresponds better than Abeta42 to amyloid PET in Alzheimer's disease. J Alzheimers Dis. 2017;55:813–22.
pubmed: 27792012
Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154–65.
pubmed: 27042676 pmcid: 4774260
Lozoya-Delgado P, Ruiz-Sanchez de Leon JM, Pedrero-Perez EJ. [Validation of a cognitive complaints questionnaire for young adults: the relation between subjective memory complaints, prefrontal symptoms and perceived stress]. Rev Neurol. 2012;54:137–50.
pubmed: 22278890
Alegret M, Espinosa A, Valero S, Vinyes-Junque G, Ruiz A, Hernandez I, et al. Cut-off scores of a brief neuropsychological battery (NBACE) for Spanish individual adults older than 44 years old. PLoS ONE. 2013;8:e76436.
pubmed: 24146868 pmcid: 3797837
Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210–7.
pubmed: 21764791
Sanabria A, Alegret M, Rodriguez-Gomez O, Valero S, Sotolongo-Grau O, Monte-Rubio G, et al. The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in subjective cognitive decline. Sci Rep. 2018;8:3828.
pubmed: 29491481 pmcid: 5830648
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
pubmed: 1202204
Kent P. The evolution of the Wechsler Memory Scale: a selective review. Appl Neuropsychol Adult. 2013;20:277–91.
pubmed: 23445503
Franzmeier N, Caballero MÁA, Taylor ANW, Simon-Vermot L, Buerger K, Ertl-Wagner B et al. Resting-state global functional connectivity as a biomarker of cognitive reserve in mild cognitive impairment. Brain Imaging Behav 2016;11:368–82.
Franzmeier N, Duering M, Weiner M, Dichgans M, Ewers M, Alzheimer's Disease Neuroimaging I. Left frontal cortex connectivity underlies cognitive reserve in prodromal Alzheimer disease. Neurology. 2017;88:1054–61.
pubmed: 28188306 pmcid: 5384837
Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci. 2003;23:6690–4.
pubmed: 12890761 pmcid: 6740735
Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol. 2018;17:241–50.
pubmed: 29397305 pmcid: 5816717
Araque Caballero MA, Brendel M, Delker A, Ren J, Rominger A, Bartenstein P, et al. Mapping 3-year changes in gray matter and metabolism in Abeta-positive nondemented subjects. Neurobiol Aging. 2015;36:2913–24.
pubmed: 26476234
Pasquini L, Scherr M, Tahmasian M, Meng C, Myers NE, Ortner M et al. Link between hippocampus' raised local and eased global intrinsic connectivity in AD. Alzheimers Dement 2014;11:475–84.
Ebeling U, von Cramon D. Topography of the uncinate fascicle and adjacent temporal fiber tracts. Acta Neurochir (Wien). 1992;115:143–8.
Von Der Heide RJ, Skipper LM, Klobusicky E, Olson IR. Dissecting the uncinate fasciculus: disorders, controversies and a hypothesis. Brain. 2013;136(Pt 6):1692–707.
Anderson KL, Rajagovindan R, Ghacibeh GA, Meador KJ, Ding M. Theta oscillations mediate interaction between prefrontal cortex and medial temporal lobe in human memory. Cereb Cortex. 2010;20:1604–12.
pubmed: 19861635
Spaniol J, Davidson PS, Kim AS, Han H, Moscovitch M, Grady CL. Event-related fMRI studies of episodic encoding and retrieval: meta-analyses using activation likelihood estimation. Neuropsychologia. 2009;47:1765–79.
pubmed: 19428409
Grady CL, McIntosh AR, Craik FI. Age-related differences in the functional connectivity of the hippocampus during memory encoding. Hippocampus. 2003;13:572–86.
pubmed: 12921348
Axmacher N, Schmitz DP, Wagner T, Elger CE, Fell J. Interactions between medial temporal lobe, prefrontal cortex, and inferior temporal regions during visual working memory: a combined intracranial EEG and functional magnetic resonance imaging study. J Neurosci. 2008;28:7304–12.
pubmed: 18632934 pmcid: 6670397
Harris AZ, Gordon JA. Long-range neural synchrony in behavior. Annu Rev Neurosci. 2015;38:171–94.
pubmed: 25897876 pmcid: 4497851
Wang L, Zang Y, He Y, Liang M, Zhang X, Tian L, et al. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage. 2006;31:496–504.
pubmed: 16473024
Zhang Y, Simon-Vermot L, Araque Caballero MA, Gesierich B, Taylor AN, Duering M, et al. Enhanced resting-state functional connectivity between core memory-task activation peaks is associated with memory impairment in MCI. Neurobiol Aging. 2016;45:43–49.
pubmed: 27459924
Henseler I, Falkai P, Gruber O. Disturbed functional connectivity within brain networks subserving domain-specific subcomponents of working memory in schizophrenia: relation to performance and clinical symptoms. J Psychiatr Res. 2010;44:364–72.
pubmed: 19837416
Meyer-Lindenberg AS, Olsen RK, Kohn PD, Brown T, Egan MF, Weinberger DR, et al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry. 2005;62:379–86.
pubmed: 15809405
Alvarez-Salvado E, Pallares V, Moreno A, Canals S. Functional MRI of long-term potentiation: imaging network plasticity. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130152.
pubmed: 24298154 pmcid: 3843884
Boots EA, Schultz SA, Clark LR, Racine AM, Darst BF, Koscik RL, et al. BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention. Neurology. 2017;88:2098–106.
pubmed: 28468845 pmcid: 5447398
Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis BM, et al. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci. 2009;29:9321–9.
pubmed: 19625522 pmcid: 3411546
Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE, et al. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS ONE. 2009;4:e5424.
pubmed: 19412541 pmcid: 2671606
Lim YY, Rainey-Smith S, Lim Y, Laws SM, Gupta V, Porter T, et al. BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. Int Psychogeriatr. 2017;29:1825–34.
pubmed: 28720165
Krasnow B, Tamm L, Greicius MD, Yang TT, Glover GH, Reiss AL, et al. Comparison of fMRI activation at 3 and 1.5T during perceptual, cognitive, and affective processing. Neuroimage. 2003;18:813–26.
pubmed: 12725758
Day GS, Musiek ES, Roe CM, Norton J, Goate AM, Cruchaga C, et al. Phenotypic similarities between late-onset autosomal dominant and sporadic alzheimer disease: a single-family case-control study. JAMA Neurol. 2016;73:1125–32.
pubmed: 27454811 pmcid: 5025942
Chhatwal JP, Schultz AP, Johnson KA, Hedden T, Jaimes S, Benzinger TLS, et al. Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. Brain. 2018;141:1486–500.
pubmed: 29522171 pmcid: 5917745
Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther. 2011;3:1.
pubmed: 21211070 pmcid: 3109410
Joshi A, Ringman JM, Lee AS, Juarez KO, Mendez MF. Comparison of clinical characteristics between familial and non-familial early onset Alzheimer's disease. J Neurol. 2012;259:2182–8.
pubmed: 22460587 pmcid: 3442121
Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66:1537–44.
pubmed: 20008660
Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H, et al. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med. 1998;4:452–5.
pubmed: 9546792
Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol. 2006;253:139–58.
pubmed: 16267640
Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389–404.
pubmed: 16906426 pmcid: 3906709
Schultz AP, Chhatwal JP, Hedden T, Mormino EC, Hanseeuw BJ, Sepulcre J, et al. Phases of hyperconnectivity and hypoconnectivity in the default mode and salience networks track with amyloid and tau in clinically normal individuals. J Neurosci. 2017;37:4323–31.
pubmed: 28314821 pmcid: 5413178
Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787–800.
pubmed: 26344059 pmcid: 4900162
Mackay CP, Kuys SS, Brauer SG. The effect of aerobic exercise on brain-derived neurotrophic factor in people with neurological disorders: a systematic review and meta-analysis. Neural Plast. 2017;2017:4716197.
pubmed: 29057125 pmcid: 5625797
Vaynman S, Ying Z, Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur J Neurosci. 2004;20:2580–90.
pubmed: 15548201
Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009;5:311–22.
pubmed: 19498435

Auteurs

Nicolai Franzmeier (N)

Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.

Jinyi Ren (J)

Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.

Alexander Damm (A)

Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.

Gemma Monté-Rubio (G)

Fundació ACE, Alzheimer Treatment and Research Center, Barcelona, Spain.

Mercè Boada (M)

Fundació ACE, Alzheimer Treatment and Research Center, Barcelona, Spain.
CIBERNED, Center for Networked Biomedical Research on Neurodegenerative Diseases, National Institute of Health Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain.

Agustín Ruiz (A)

Fundació ACE, Alzheimer Treatment and Research Center, Barcelona, Spain.
CIBERNED, Center for Networked Biomedical Research on Neurodegenerative Diseases, National Institute of Health Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain.

Alfredo Ramirez (A)

Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany.
Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.

Frank Jessen (F)

Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Emrah Düzel (E)

German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.

Octavio Rodríguez Gómez (O)

Fundació ACE, Alzheimer Treatment and Research Center, Barcelona, Spain.
CIBERNED, Center for Networked Biomedical Research on Neurodegenerative Diseases, National Institute of Health Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain.

Tammie Benzinger (T)

Department of Radiology, Washington University in St Louis, St Louis, MO, USA.
Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.

Alison Goate (A)

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Celeste M Karch (CM)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.
Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA.

Anne M Fagan (AM)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.

Eric McDade (E)

Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.

Katharina Buerger (K)

Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.

Johannes Levin (J)

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany.

Marco Duering (M)

Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.

Martin Dichgans (M)

Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Marc Suárez-Calvet (M)

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Barcelonabeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Catalonia, Spain.
Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.

Christian Haass (C)

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.

Brian A Gordon (BA)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Mallinckrodt Institute of Radiology, Washington University, St. Louis, MO, USA.
Department of Psychological and Brain Sciences, Washington University, St. Louis, MO, USA.

Yen Ying Lim (YY)

The Florey Institute, The University of Melbourne, Parkville, VIC, Australia.

Colin L Masters (CL)

The Florey Institute, The University of Melbourne, Parkville, VIC, Australia.

Daniel Janowitz (D)

Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.

Cihan Catak (C)

Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.

Steffen Wolfsgruber (S)

Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Michael Wagner (M)

Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Esther Milz (E)

Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany.

Sonia Moreno-Grau (S)

Fundació ACE, Alzheimer Treatment and Research Center, Barcelona, Spain.
CIBERNED, Center for Networked Biomedical Research on Neurodegenerative Diseases, National Institute of Health Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain.

Stefan Teipel (S)

German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Department of Psychosomatic Medicine, University Hospital Rostock, Rostock, Germany.

Michel J Grothe (MJ)

German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.

Ingo Kilimann (I)

German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.

Martin Rossor (M)

Dementia Research Centre, University College London, Queen Square, London, UK.

Nick Fox (N)

Dementia Research Centre, University College London, Queen Square, London, UK.

Christoph Laske (C)

Hertie Institute for Clinical Brain Research, Tübingen, Germany.
Germany and German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Jasmeer Chhatwal (J)

Massachusetts General Hospital, Department of Neurology, Harvard Medical School, Boston, MA, USA.

Peter Falkai (P)

Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany.

Robert Perneczky (R)

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, Munich, Germany.
Neuroepidemiology and Ageing Research Unit, School of Public Health, The Imperial College of Science, Technology and Medicine, London, UK.

Jae-Hong Lee (JH)

Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Annika Spottke (A)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department of Neurology, University of Bonn, Bonn, Germany.

Henning Boecker (H)

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Department of Radiology, University of Bonn, Bonn, Germany.

Frederic Brosseron (F)

Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Klaus Fliessbach (K)

Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Michael T Heneka (MT)

Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Peter Nestor (P)

German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia.

Oliver Peters (O)

German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany.

Manuel Fuentes (M)

German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany.

Felix Menne (F)

German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany.

Josef Priller (J)

German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Department of Neuropsychiatry, Charité, Berlin, Germany.

Eike J Spruth (EJ)

German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Department of Neuropsychiatry, Charité, Berlin, Germany.

Christiana Franke (C)

German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Department of Neuropsychiatry, Charité, Berlin, Germany.

Anja Schneider (A)

Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Christine Westerteicher (C)

Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

Oliver Speck (O)

German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Leibniz Institute for Neurobiology, Magdeburg, Germany.
Center for Behavioral Brain Sciences, Magdeburg, Germany.
Department for Biomedical Magnetic Resonance, Institute for Physics, Otto-von-Guericke University, Magdeburg, Germany.

Jens Wiltfang (J)

German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany.
iBiMED, Medical Sciences Department, University of Aveiro, Aveiro, Portugal.

Claudia Bartels (C)

Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany.

Miguel Ángel Araque Caballero (MÁ)

Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.

Coraline Metzger (C)

German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.

Daniel Bittner (D)

German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.

Stephen Salloway (S)

Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA.

Adrian Danek (A)

Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany.

Jason Hassenstab (J)

Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.

Igor Yakushev (I)

Department of Nuclear Medicine, Technical University of Munich, Munich, Germany.

Peter R Schofield (PR)

Neuroscience Research Australia, Barker Street Randwick, Sydney, NSW, 2031, Australia.
School of Medical Sciences, University of New South Wales, Sydney, NSW, 2052, Australia.

John C Morris (JC)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA.
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.

Randall J Bateman (RJ)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.

Michael Ewers (M)

Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany. michael.ewers@med.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH